Amgen Inc. $AMGN Shares Sold by Whittier Trust Co.

Whittier Trust Co. cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 34.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 47,811 shares of the medical research company’s stock after selling 24,827 shares during the period. Whittier Trust Co.’s holdings in Amgen were worth $15,786,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. boosted its stake in Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock valued at $15,204,047,000 after purchasing an additional 165,281 shares during the period. Capital International Investors raised its holdings in shares of Amgen by 1.5% in the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after purchasing an additional 282,219 shares in the last quarter. Capital World Investors raised its holdings in shares of Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares in the last quarter. Capital Research Global Investors raised its holdings in shares of Amgen by 2.7% during the third quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock valued at $1,335,168,000 after acquiring an additional 122,631 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of Amgen by 6.6% during the third quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company’s stock valued at $1,260,668,000 after acquiring an additional 277,031 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AMGN. Daiwa Securities Group boosted their price target on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Truist Financial boosted their price objective on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. The Goldman Sachs Group boosted their price objective on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Finally, TD Cowen restated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $356.24.

Amgen Trading Up 0.3%

Shares of Amgen stock opened at $349.39 on Friday. The stock has a market capitalization of $188.56 billion, a P/E ratio of 24.55, a price-to-earnings-growth ratio of 3.28 and a beta of 0.47. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a 50-day simple moving average of $363.49 and a 200 day simple moving average of $336.75. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s dividend payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.